Beyond ISS staging: the prognostic value of the Inflammation Prognostic Score Index (IPSI) in multiple myeloma

Xiaomei Huang; Jing Wu; Shiying Li; Qinglan Lu; Xunjun Huang; Ruolin Li

doi:10.1080/16078454.2025.2549959

September 1, 2025HematologyOpen Access

Beyond ISS staging: the prognostic value of the Inflammation Prognostic Score Index (IPSI) in multiple myeloma

View Full Paper

Ask AI

Bookmark

Share

Key Points

The IPSI provides significant prognostic value beyond the ISS in multiple myeloma patients.
Newly diagnosed MM patients benefiting from IPSI showed improved risk assessment metrics compared to ISS.
The study establishes IPSI as a complementary tool, enhancing staging accuracy for better clinical outcomes.
Integration of IPSI may lead to more tailored treatment protocols for patients with multiple myeloma.

Implication

Assessment of IPSI enhances prognostic capabilities in newly diagnosed multiple myeloma, suggesting a valuable addition to ISS.

Abstract

Objectives To establish a novel Inflammation Prognostic Score Index (IPSI) and evaluate its prognostic value and complementary role to the International Staging System (ISS) in newly diagnosed multiple myeloma (MM).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Huang et al. (2025) studied this question.

synapsesocial.com/papers/68bb49c46d6d5674bccffa7e https://doi.org/10.1080/16078454.2025.2549959

View Full Paper

Ask AI

Bookmark

Share

Beyond ISS staging: the prognostic value of the Inflammation Prognostic Score Index (IPSI) in multiple myeloma

Key Points

Implication

Abstract

Discussion

Cite This Study

Beyond ISS staging: the prognostic value of the Inflammation Prognostic Score Index (IPSI) in multiple myeloma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading